Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976284 | 1.00 | CTSB (0.42) | CTSBCTSSCYP3A4HDAC4HDAC1 | |
| SCHEMBL11976283 | 0.90 | CTSB (0.41) | CTSBCTSSHDAC4HDAC1 | |
| SCHEMBL12820534 | 0.89 | CTSB (0.41) | CTSBCTSS | |
| Hydrochloric Acid SCHEMBL1683100 | 0.89 | CTSB (0.41) | CTSBCTSS | |
| Hydrochloric Acid SCHEMBL4522873 | 0.89 | CTSB (0.41) | CTSBCTSS | |
| SCHEMBL16242466 | 0.88 | CTSB (0.41) | CTSBCTSSCYP3A4 | |
| SCHEMBL13896373 | 0.88 | CTSB (0.41) | CTSBCTSSCYP3A4 | |
| SCHEMBL16242468 | 0.88 | CTSB (0.41) | CTSBCTSSCYP3A4 | |
| SCHEMBL16242467 | 0.88 | CTSB (0.41) | CTSBCTSSCYP3A4 | |
| SCHEMBL8249221 | 0.88 | CTSB (0.41) | CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829665-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169510-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | CTSB 550/4885CTSS 916/4885CYP3A4 826/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | CTSB 550/4885CTSS 916/4885CYP3A4 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.